AstraZeneca has told the FDA it is discontinuing both exenatide products — short-acting Byetta (Oct 25, 2024) and once-weekly Bydureon BCise (Oct 28, 2024) — ending the run of the first GLP-1 drug ever approved in the United States. Insurer guidance points patients to newer preferred GLP-1s such as semaglutide and tirzepatide; the exit is a business decision in a crowded class, not a safety recall.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.